FountainVest Is Said to Be Last Bidder for ZF's Lifetec Unit
FountainVest is trying to hammer out key terms of a deal for the ZF Lifetec unit, the people said, declining to be identified because the information is private. There's still a wide gap on price expectations and there's no certainty they will be able to reach an agreement, according to the people.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
U.S. citizen who works for Commerce Dept. ensnared in Chinese exit ban
A Chinese American man who works for the Commerce Department and traveled to China several months ago is being prevented from leaving the country after he failed to disclose on his visa application that he worked for the U.S. government, according to four people familiar with the matter. The American, an employee of the Patent and Trademark Office, went to China to visit family and now has been caught up in China's controversial practice of blocking Chinese and foreign nationals from leaving China — in what is often seen by Washington as a tool of coercion against people and businesses, these people said. All spoke on the condition of anonymity because of the matter's sensitivity.
New York Times
an hour ago
- New York Times
As Trump Courts a More Assertive Beijing, China Hawks Are Losing Out
In recent years, one of China's biggest requests of American officials has been that the United States relax its strict controls on advanced artificial intelligence chips, measures that were put in place to slow Beijing's technological and military gains. Last week, the Trump administration did just that, as it allowed the world's leader in A.I. chips, the U.S.-based Nvidia, to begin selling a lower-level but still coveted chip known as H20 to China. The move was a dramatic reversal from three months ago, when President Trump himself banned China from accessing the H20, while also imposing triple-digit tariffs on Beijing. That set off an economically perilous trade clash, as China retaliated by clamping down on exports of minerals and magnets that are critical to American factories, including automakers and defense manufacturers. China's decision to cut off access to those materials upended the dynamic between the world's largest economies. The Trump administration, which came into office determined to bully China into changing its trade behavior with punishing tariffs, appeared to realize the perils of that approach. Now, the administration has resorted to trying to woo China instead. Officials throughout the government say the Trump administration is putting more aggressive actions on China on hold, while pushing forward with moves that the Chinese will perceive positively. That includes the reversal on the H20 chip. The H20 decision was primarily motivated by top Trump officials who agreed with Nvidia's arguments that selling the chip would be better for American technology leadership than withholding it, people familiar with the move say. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Carl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years ago
If you love investing in stocks you're bound to buy some losers. Long term Carl Zeiss Meditec AG (ETR:AFX) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 63% in that time. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Carl Zeiss Meditec's earnings per share (EPS) dropped by 16% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. A Different Perspective While the broader market gained around 23% in the last year, Carl Zeiss Meditec shareholders lost 16% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Carl Zeiss Meditec better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Carl Zeiss Meditec , and understanding them should be part of your investment process. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
